Connaught Labs' acellular pertusis vaccine
Executive Summary
PLA filed for bivalent acellular vaccine, firm said Jan. 11, for innoculation at 18 months of age. The vaccine, licensed for the U.S. from Biken, Japan, was studied in Japan and Sweden on children from three months to two years old and in U.S. trials in 18-month olds. Connaught said it is continuing to conduct studies in infants 2-6 months old, "but feels current results warrant" the PLA filing for 18-month olds.